Product information and disease descriptionProduct descriptionProduct informationDosing and administration
Dosage
1 evidence topic · 1 source
Zipalertinib (CLN-081)
EGFR exon 20 insertion-mutated non-small-cell lung cancer
- Manufacturer
- Taiho Oncology
- Regulatory submission
- NDA submitted February 2026
- Launch
- Not announced
- Last updated